Corcept Therapeutics Incorporated

Good day, and thank you for standing by. Welcome to the CORE-CEP therapeutic conference call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press star 11 again. Please be advised, today's conference is being recorded. I would like to turn the call over to Adibak Makkari. Please go ahead.

Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the fourth quarter and providing a corporate update. The copy is available at coursef.com. Our complete financial results will be available when we file our Form 10-K with the SEC. Today's call is being recorded. A replay will be available at the Investors Past Events tab of our website. Statements during this call, other than statements of historical fact, are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to differ materially from those such statements express or imply. These forward-looking statements are described in today's press release, and the risks and uncertainties that may affect them are described in the press release and in our annual report on Form 10-K and our quarterly reports on Form 10-Q. Please refer to those documents for additional information. If you disclaim any intention or duty to update forward-looking statements. Our revenue in the fourth quarter of 2023 was $135.4 million, an increase of 31% compared to the fourth quarter of the prior year. We expect our revenue growth to continue and are reiterating 2024 revenue guidance of $600 to $630 million, compared to 2023 revenue of $482.4 million. Net income was $31.4 million in the fourth quarter and $106.1 million for the full year 2023. Our cash and investments at December 31st was $425.4 million. I will now turn the call over to Charlie Robb, our Chief Business Officer, to provide a legal update.

Charlie? Thanks, Adivac. In March 2018, we sued Teva Pharmaceuticals to prevent it from marketing a generic version of Quarlem in violation of our patents. The case went to trial in federal district court in September of last year. On December 29th, the court found that Teva's generic product would not infringe the two patents we had asserted against it. We believe the court's verdict is wrong and is based on a misunderstanding of the law. Accordingly, we are seeking its reversal by the Federal Circuit Court of Appeals. It is impossible to predict exactly how long the appeal will take. Briefing will be complete no later than May. Our opening brief is due March 9th. TEVA will have up to 40 days after we file to respond. Our reply brief, closing the briefing cycle, will be due no later than 21 days after that. These documents will all be publicly available on the internet at the PACER website. With briefing complete, the timing of oral argument and issuance and opinion are entirely up to the court. Based on past practice, it's reasonable to expect oral argument in the fourth quarter of this year and a decision early in the first quarter of 2025. If we prevail, TEVA would lose FDA approval of its product, at least until the expiration of our patents in 2037. We are here to advance this appeal. This has always been the case. We strongly believe that our position is the correct one. We are confident that the Federal Circuit, with its deep expertise in this area of the law, will agree. I will now turn the call over to Joe Belanoff, our Chief Executive Officer. Joe? Thank you, Charlie.

And thank you, everyone, for joining us this afternoon. Ottobock highlighted our strong commercial performance and the revenue guidance we have set for 2024. A few weeks ago, I had the opportunity to meet with our endocrinology team at our national field meeting. The enthusiasm about our prospects in hypercortisolism was palpable. We have the opportunity to help many more patients with Cushing syndrome. We are reaching a tipping point of sorts, with the medical field increasingly understanding that hypercortisolism is far more prevalent than was previously assumed. Our ongoing phase four catalyst study will reinforce this emerging understanding And I believe this study will be a landmark in guiding the future screening and accurate diagnosis of patients with Cushing syndrome. Catalyst is the largest clinical trial ever conducted to examine the prevalence of hypercortisolism in patients with difficult-to-treat type 2 diabetes. Its investigators are, unquestionably, the country's top diabetologists. Today, we announce preliminary results from the first 700 patients enrolled. Those results showed a hypercortisolism prevalence rate of 24%, far higher than many in the medical community have believed to be the case in this population. This is a two-part study. The prevalence portion of Catalyst continues to enroll patients. Those diagnosed with hypercortisolism can enroll in the treatment phase. The final results from the prevalence phase will be presented in a keynote session at the American Diabetes Association's annual meeting in June. The results of the CATALYST study will undoubtedly stimulate physicians to screen patients for hypercortisolism, and many more than are currently identified will be found. Corsept is well-positioned to help them. For more than a decade, we have invested in patient advocacy and education and patient support services that are all based on understanding the journey and needs of an individual diagnosed with hypercortisolism. Our team is proud of these programs, and we are prepared to help what we know will be a growing number of patients in the years to come. As the awareness and diagnosis of Cushing syndrome increases, we are working with a great sense of urgency to advance relacoralin. This sense of urgency comes from knowing that the compound has compelling efficacy without many of the significant side effects of coralline. All of our proprietary compounds, including relacoralin, modulate cortisol's effects by binding to the glucocorticoid receptor, receptor, which is activated when cortisol levels are high. They do not bind to the progesterone receptor and therefore don't cause some of coralline's most serious off-target effects. We are evaluating relacoralline for the treatment of hypercortisolism in two phase three trials, GRACE and GRADIENT. We expect GRACE to serve as the basis for our NDA submission in Cushing syndrome and to build on relacoralline's positive phase two efficacy and safety data. Patients experienced meaningful improvements in hypertension and glucose control, as well as the other signs of symptoms of Cushing syndrome in the Phase II study. Relacoralin did not cause progesterone-related side effects, including endometrial thickening or vaginal bleeding. Relacoralin also did not cause drug-induced hypokalemia. Progesterone-related side effects and hypokalemia are leading causes of coralline discontinuation. Relacoralin's phase 2 trial results were published in Frontiers in Endocrinology in July 2021. Our second phase 3 trial in hypocortisolism, Gradient, is studying relacoralin's effects in patients whose Cushing syndrome is caused by an adrenal adenoma or adrenal hyperplasia. Patients with this etiology of Cushing syndrome often experience a less rapid decline, but their health outcomes are poor, including a significantly higher risk of premature death. While we do not expect our NDA and Cushing syndrome to depend on efficacy data from gradient, we do expect the study to provide valuable information about the treatment of an etiology of Cushing syndrome that affects many patients. It bears repeating that the first phase of our ongoing phase four catalyst study reinforces the findings from many smaller studies indicating that hypercorizalism is far more prevalent than was previously assumed. The findings from CATALYST will be entirely relevant to relacoralin as it emerges. As I said, we are working with great urgency, and we are on track to submit a relacoralin Cushing syndrome NDA in the second quarter. We are also studying relacoralin as a treatment for different types of cancer. Our most advanced oncology program is in platinum-resistant ovarian cancer, a lethal cancer with few useful treatment options. There was great enthusiasm among the investigators participating in our phase three Rosella trial. Enrollment in the study will close shortly and data will be available by the end of this year. The goal of Rosella is simply to replicate our positive phase two ovarian cancer trial results. Rosella's study design closely tracks our phase two study with a planned enrollment of 360 women. Women enrolled in the study are randomized one to one to receive either relacoralin plus napaclitaxel or napaclitaxel alone. The primary endpoint is progression-free survival, with overall survival a key secondary endpoint. We are conducting this study in collaboration with leading clinicians from the Gynecological Oncology Group, GOG, in the United States, and the European Network of Gynecological Oncology Trials, NGOT group, in Europe. In our successful controlled phase two trial, relacoralin produced meaningful benefit to many women. While these women's disease had progressed on two or more previous lines of treatment, including previous taxanes, relacoralin appeared to resensitize their tumors to chemotherapy's beneficial effects. Those who received relacoralin intermittently, the day before, the day of, and the day after they received napaclitaxel, exhibited statistically significant improvement in progression-free survival and duration of response compared to the group who received nabpaclitaxel monotherapy. Women in the intermittent relacoralin group also lived longer than those in the comparator arm. 29% of the patients who took intermittent relacoralin were alive two years after study start, versus only 14% who took nabpaclitaxel alone. The addition of relacoralin enhanced the effect of chemotherapy, likely by blunting cortisol's anti-apoptotic effect. Just as important, the women who received relucoralin plus nipaquitaxel experienced no additional side effect burden compared to those who took nipaquitaxel alone. The results from this study were published in the Journal of Clinical Oncology in June 2023 with an accompanying editorial. Results have been featured in podium presentations in the 2021 and 2022 European Society for Medical Oncology ESMO meetings and at the 2022 American Society of Clinical Oncology ASCO annual meeting. Leading gynecological oncologists have told us that relucorolin's potential benefit, improved progression-free and overall survival without increased side effect burden, would constitute an important medical advance and that relicoralin plus napaclitaxel has the potential to become a new standard of care in women with platinum-resistant ovarian cancer. A second mechanism by which cortisol modulation may prove useful is by blocking in an important tumor growth pathway. Cortisol stimulation is a major reason why patients with prostate cancer treated with a widely prescribed androgen receptor antagonist enzalutamide eventually experience resurgent disease. Deprived of androgen stimulation, their tumors switch to cortisol activity to stimulate growth. Our hypothesis is that adding a cortisol modulator to androgen deprivation therapy will close this tumor escape route. Our collaborators at the University of Chicago are enrolling a randomized placebo-controlled Phase II trial of relacoralin plus enzalutamide in patients with prostate cancer. before these patients have had an initial prostatectomy. A third cortisol modulation mechanism seeks to treat tumors by enhancing the body's immune response. Cortisol suppresses the immune system, which may blunt the effectiveness of cancer therapies intended to stimulate the immune system. Our hypothesis is that adding a cortisol modulator to immunotherapies, such as checkpoint inhibitors, may enhance the effectiveness of these therapies. We are conducting a phase 1B trial of relucorolin plus the PD-1 checkpoint inhibitor pembrolizumab in patients with advanced adrenal cancer whose tumors produce excess cortisol. Pembrolizumab is rarely effective as monotherapy in treating this form of adrenal cancer. While each of our compounds being evaluated in clinical studies selectively modulates cortisol activity, they are not identical and they produce distinct clinical effects. Some cross the blood-brain barrier, others do not. Some perform best in models of solid tumors, others are more potent in models of metabolic disease. Some appear to be tissue-specific, others have more global effects. These diverse qualities allow us to study a wide variety of disorders using the best matched compound. One of these compounds, dazocoralate, has shown great promise in animal models of ALS, improving motor performance, and reducing neuroinflammation and muscular atrophy. As you know, ALS is a devastating disease with a very poor prognosis and limited options to halt or slow its progression. Our DASLS trial is a randomized, double-blind, placebo-controlled phase 2 trial of DASL-Coralin in patients with ALS. The primary endpoint is based on the ALS functional rating scale. The speed of enrollment in DASLS exceeded our expectations. Enrollment will close shortly, with data available by the end of this year. Finally, I'll turn to our program in NASH, a serious liver disorder that afflicts millions of people in the United States. Miracoralin has demonstrated compelling early evidence as a treatment for NASH. Our Phase 1B dose-binding study found that patients who received 100 milligrams of Miracoralin orally twice a week for 12 weeks experienced a 30% reduction in liver fat with improvement in liver enzymes, markers of fibrosis, and key metabolic and lipid measures, including HOMA-IR, serum triglycerides, and LDL. Importantly, miracluralin was also very well tolerated with no apparent GI side effects. We look forward to building on these promising results in our MONARCH study, a randomized, double-blind, placebo-controlled base 2B trial now actively enrolling patients with biopsy-confirmed NASH. The primary endpoint of the study is reduction of liver fat, with NASH resolution and fibrosis improvement as key secondary endpoints. In conclusion, we are extremely optimistic about the future of CoreSeptic. Our Cushing's syndrome franchise is built on a solid foundation, a foundation that is supported by scientific, medical, and commercial expertise that we have been strengthening and honing for over 20 years. Our strong commercial results reflect that physicians are more regularly screening for hypercortisolism and underscore our ability to support them as they manage this complex disease. We expect the findings from our catalyst study to help physicians better identify and treat patients whose difficult-to-treat diabetes is caused by hypercortisolism, a population whose Cushing syndrome too frequently goes missed or undiagnosed. Relacoralin has demonstrated tremendous promise as a treatment for patients with Cushing syndrome, and we are on track to submit our NDA in the second quarter. Beyond Cushing syndrome, our development programs are generating increasing evidence that cortisol modulation has the potential to treat a wide range of diseases. Ovarian cancer, prostate cancer, ALS, and NASH are current examples. We have a broad and active research portfolio of many proprietary selections, cortisol modulators with potentially very different clinical attributes. We will continue to invest in understanding these attributes and their potential therapeutic applications, and we will advance the most promising compounds to the clinic. Over the course of this year, we expect data from our GRACE, GRADIENT, and CATALYST studies in Cushing syndrome, our pivotal ROSELLA trial in ovarian cancer, and our DAZZLES trial in ALS. This is an exciting time for CORSEP. I appreciate the efforts and dedication of our more than 350 employees who are working hard to achieve the ambitious goals we have set for ourselves. Before we take questions, I want to take a moment to introduce Roberto Vieira, who joined Corecept a few years ago. Roberto, as president of our oncology division, is responsible for the commercialization of reliquaryland and platinum-resistant ovarian cancer and the expansion of our oncology footprint. You'll have an opportunity to hear more from him over the course of 2024. Operator, let's proceed now to questions.

Thank you. If you would like to ask a question, please press star 11 on your telephone. As a reminder, please wait for your name and company to be called before you proceed with your question. One moment while we compile the Q&A roster.

Our first question for the day will be coming from Matt Kaplan of Lindenburg.

Your line is open.

Hey, guys. Thanks for taking the question. Just wanted to start off first with your rewriting your guidance of 600 to 630 million for 2024. Can you give us a little bit more color in terms of, I guess, given the court's recent decision on the Teva case, why you're still confident and why you're reiterating the guidance that you had given before the court's decision.

Just one small point, but good to hear from you, Matt. Our guidance came after the court's decision, but we are reiterating it here. Sean Duke, who's president of our endocrinology division, will take this question.

Matt, thank you for the question. Our revenue guidance will always consider all the information that we have and our best estimates going forward. Our range includes a multitude of factors, including a potential type of launch and its impact. We have reiterated the range of 600 to 630 because we're confident in our ability to both grow our own business and to defend our market share.

And then in terms of, I guess maybe for Charlie, the legal update, You said that you remain confident in terms of being able to win the argument as you appeal the court's decision. Can you give us some more color in terms of where you thought, where you think the court erred in this decision and why you think you'll be able to reverse it?

Yeah, I mean, unfortunately, Matt, I really can't share sort of our, you know, legal sort of deliberations as we work through. Obviously, I've given the matter a great deal of thought. But what I can say is, you know, what will really matter and what will be available to you and everyone is the briefs as we file it. And I'm really going to have to let them speak for themselves. And, you know, we'll shortly be submitting our brief and you and everyone can take a look at it then. And that's really the most I can tell you at this point.

Okay, fair enough. And then... I guess congrats on the initial results in the catalyst study, 24% prevalence of hypocortisolism. That's higher than, I guess, we had expected. How does this translate, help us translate this into potential market size and numbers of patients, given that result?

Yeah, Matt, I'll take that question. I think it's just really critical for people to understand that many people thought that the answer to that prevalence rate was going to be zero or zero to a couple of percent. Now, that wasn't borne out by earlier evidence. There were many studies over the last decade that indicated in this group of patients, patients who have otherwise refractory diabetes, difficult to treat diabetes, that the results were substantial. There were substantial groups of patients with that. But no one had ever attempted as large a study in the way we did it prospectively or, frankly, with the level of investigators who actually participated in this study. So I don't know exactly how that is going to reflect in what the final prevalence turns out to be. But what I can tell you is that it's substantially higher than what has previously been assumed. What's been previously assumed, I'll remind you, because we said it many times on this call, there were about 20,000 patients who had Cushing syndrome and about half of them were cured by surgery. It's very clear to us right now that the actual overall prevalence for Cushing syndrome is considerably higher than that.

All right. Well, I'll jump back in the queue. Thanks for taking my question. Thank you, Matt. Thanks.

Thank you.

One moment for our next question. And our next question is from .

Your line is open.

Hi, team. Congrats on the results, and thank you for taking the questions from us. So we understand that when a patient stops taking Cortland, the cortisol levels begin to rebound within four to five weeks. And the randomized risk growth in the GRACE study is 12 weeks. So how confident are we that a statistical significance

difference in the changes of blood pressure would be observed during that 12-week window i'm not sure i really understood the question and so please tell me if in the end i haven't answered what you said but i think the question had to do with for patients who were successfully treated with coralum how how long does it take for um stopping uh for when you stop quarreling for their uh effects of the coralline effects to rebound. And now we remember we're talking at this moment about coralline, not relacoralline. Our experience was much quicker than I think what I heard you said. Usually within a couple of weeks, we actually see rebound from patients who stop taking coralline, which frankly is a compelling reason for the high adherence rate we see with coralline is that when they stop taking their medicine, they get pretty much worse pretty quickly. We actually expect same sort of timeline with relic correlant as that. Obviously, the study will give us the results to that, but we think that we have a more than substantial length of time in order to see the rebound effect that comes from not taking relic correlant in the upcoming study.

Okay, thank you.

Thank you. One moment for the next question. And our next question will be coming from David Asselin of Piper Jaffer.

Your line is open.

Hey, thanks. So I just had a few. So I wanted to come back to, you know, the generic of Corlin, and I get your comments. I guess I just wanted to get more color on the barriers to generic adoption that you think are in place, the In other words, the specialty hub that serves all of these sort of high touch points that are related to Coraline. Is that something that ultimately proves to be a barrier to generics? And can you just talk about those dynamics? So that's number one. And then secondly, you're talking about filing. I'm sorry, filing in the second quarter on Relic Coraline, but you're also going to have top line data in the second quarter. So that's kind of a tight turnaround. So can you just talk about uh about that and and why you're confident you can file it so quickly um and then lastly are you going to be running any additional trials on relic orlin to tease out long-term health benefits and just talk about additional clinical work you might do to support that product thank you okay so three different questions in three different areas david thank you the first one i'm going to point to uh sean

talk about uh how we run our endocrinology business go ahead yeah no thank you for the question and your question was specifically around sort of what we believe to be barriers to entry and i'll just say that this is not your typical pharmaceutical market and supporting colon patients is far more than just filling a prescription and you know automatic substitution does not happen at a walgreens pharmacy till like you see in a lot of these cases we have a very high touch tightly controlled model every prescription that is written kicks off multiple high and the prescribing physician have the optimal experience. The only other thing I'd add here is that we spent over 12 years growing this business, and we've done that through the development of a deep understanding of the market and by building very strong relationships with providers. Coraline is a very promotionally sensitive drug, and we have all the pieces go through the initial part of the process of education of a physician through the filling of that prescription.

Charlie, would you take the question about the NDA, please? Sure. Just a little background for those who don't know this process, as I'm sure David does. A new drug application, which is what we're going to submit for reliquary and Cushing syndrome in the second quarter, really is a substantial document. It's a lot of work. And so that's why David's asking a very good question. But I think what people also may not understand is that much of the information and analysis submitted in the new drug application stems from work that is done years before the last patient leaves the pivotal study. So think of all of the preclinical research that's done, all of the phase one trials, the drug-drug interaction studies, the manufacturing development work. All this makes up a really substantial part of the NDA submission to the FDA, and we've been working on that for almost a year now. The reason we'll be able to submit this so quickly is that a great deal of the work will be complete before the last patient leaves the GRACE study. And we will be ready there to file really promptly after that. That's why we're confident.

Thank you, Charlie. And Bill Geyer, who's our chief development officer, will answer the question about relacoral and then longer-term use.

Yeah, long-term data. So thank you for that question. So there's a study that's actually ongoing that we don't talk about much. And it's a long-term extension trial. And so that is a study that is taking patients from our phase two trial. They can roll into the long-term extension trial. Grace and Gradient, when they completed those trials, they can roll into that long-term extension trial. At this point in time, we have patients out six years in that long-term extension trial. We're going to continue that study throughout to continue to provide long-term data on the safety and efficacy of reliquary patients with Cushing syndrome.

Thank you, Bill. Next question, please.

Thank you.

And one moment for the next question. And our next question will be coming from .

Your line is open.

Thank you. This is from . I have a few questions, so I'm going to kind of ask, if you don't mind, one at a time. And the first one is on the guidance itself. So you're kind of guiding. If I take the midpoint, you're guiding for like 27% increase from where we are now. And in 23, you know, you grew about 20%. So I'm just trying to understand, you know, the tremendous growth that you're expecting from where you are now. So what is included in that? You know, how much of that is price increase? And in terms of market growth itself, you know, where do you see that market growth coming from? Because in the fourth quarter, we didn't see that jump, you know, that quite of a rate compared to Q3.

I'm not... You know, RK, I think I got the questions a little bit difficult to hear. Sounded as if what you were asking was you'd like to know what are the components of the growth that we see currently in the market and where we think it's going in the future. So I think that's about right. It's not let us know, but I'll turn that over to Sean.

Yeah, no, thank you for the question. You know, in terms of, I guess, the range I mentioned earlier, it takes in a multitude of factors, and the biggest, obviously, right now is that we have more positions prescribing corallum and more patients being prescribed from each position. Over the last year and growth that we see continuing, we've added new patients from both existing and new prescribers throughout the country, and we're really pleased with the result we've seen. It's been driven by improved field execution, and we're starting to see early returns from some of the investments that we've made, both on the Salesforce side and on the disease education side. And one of the areas of growth in our business has been on the Salesforce expansion. I wanted to update you on that. In terms of where that team's at now, we're currently at about 70 clinical specialists, and we're continuing to add clinical specialists throughout the country. Our target right now is 100, and we're unlikely to stop there, and we'll continue to add top talent as we find it throughout the country. But we believe that that expansion is going to also help drive growth.

Let me just sum that up for you, RK. More doctors prescribing and more patients from each doctor. It's a trend which really got very strong towards the end of last year, and we're seeing it continue as we speak.

Is there a price increase included in this?

I couldn't hear that. Is there a price increase included in this? There's not an additional price increase included in the range for this year. We took a price increase on January 1st of this year, 9.49%. We realized about 6.5% of that, but there was no other price increase included in that number.

Okay. And then on the diabetes population itself, you know, talking about trying to understand a little bit more about how the catalyst data is going to help you out. So to start off, in terms of the percent of population, the diabetes population who are considered difficult to treat, you know, can you give us a number? Like what percentage of the diabetes population is considered that? And then do you need to do, do you need to, how do you plan to include that into your label? Is this going to be, do you need to file something or how does it work?

Yeah. So I think the answer, I think the first question you were asking, RK, was what percentage are difficult to treat diabetics? And that's specifically defined in the protocol. Patients who have hemoglobin A1Cs despite having multiple treatments and optimal care. So those patients have been on all of the modern medicines. We've been told by our expert, the diabetologist.

No, that doesn't give a percentage. That just defines who is considered that. But what percentage of population is that?

I'm getting there. The percentage of the population that, of diabetic population that's considered to be in that group difficult to treat diabetics is about a quarter.

Okay, thanks.

And the second question, Sean? Yeah, I'm happy to take the second question. So the question was, are we going to have to file to have this included within our label, this catalyst patient population? These patients are already included in our label. I'm going to read you the label right now and sort of highlight exactly that fact. What's our label or indication statement? Coraline mifepristone is a cortisol receptor blocker indicated to control hyperglycemia, secondary to hypercortisolism in adult patients with endogenous Cushing syndrome who have type 2 diabetes mellitus, or glucose intolerance and have failed surgery or are not candidates for surgery. That is a clear and exact description of the patients that are with calcine.

Next question, please.

Thank you. One moment for the next question. And we have a follow-up question from David Anselm of Piper Jeffries.

Go ahead.

Yeah, just a follow-up. So to the extent that the two other generic Sun and Hikma enter the market later this year, does that change how you think about your sales expectations, or does your 600 to 630 contemplate three generic entrants by the second half of this year? Thank you.

Here's the question.

Thank you.

Yeah, our guidance includes all those scenarios. And I just want to state that we've been thinking about this for a long time, and we've been prepared for this possibility since 2020. We have a plan in place, and we will continue to revise that plan as we receive new market intelligence. And as I said before, we're continuing to invest in our growing business, and we're confident in our ability to both grow and protect the share that we have. But yes, all of those scenarios are included in our forecast.

Thank you. One moment for the next question. And our next question will be coming from Julie of Truist.

Your line is open.

Thanks for the update, Sam, for taking our questions. So 24% of the quarter of 30 million diabetics in the US is an attractive opportunity, but the phase three grades not having hyperglycemia as an endpoint spelled out uh represent a headwind to utilization of relacorlin in diabetics or do you think the data from the gradient could be supported there and uh and also with with the you know orphan pricing of you know coralline or relacorlin be prohibited uh in the utilization and have a follow-up

Yeah, June, I'm very glad that you asked the first question because it really gives us an opportunity to really clarify what the situation is. Bill, could you please take that one?

So yeah, for the GRACE trial, we have a primary endpoint of blood pressure control and a secondary endpoint of glycemic control. And so what we do is we have a hierarchy. When we meet our blood pressure control, we plan to then have that as our primary endpoint. And therefore, we then move in that hierarchy to glucose control. And we expect to meet both of those endpoints. And we expect to have a robust response to both hypertension and diabetes control, as well as other comorbidities. And based upon meeting all those endpoints, we expect a broad indication for reliquaryland.

I think that's really an important thing. I'm just going to emphasize that I don't have anything different to say than Bill said. I want to just underscore that. Our anticipated label for reliquaryland is to treat Cushing syndrome. There are many variables that we're measuring in that study. And in the hierarchy, hypertension is at the top of the list, but glucose intolerance is on that list, as are many other endpoints that describe Cushing syndrome. I think it's probably 20 different endpoints because Cushing syndrome is a syndrome caused by excess cortisol activity. Cortisol goes everywhere in the body, and many things go wrong when people have Cushing syndrome. Now, you asked a really an interesting question about price as we go forward. And that's, you know, that really is something that we really have to think about as the market enlarges and enlarges and enlarges. And we don't know, as someone I answered to an earlier question, exactly what the market size is. But we will certainly take all those things into account as we go forward. One thing I want to just emphasize at this point is that we have not seen a single bit of influence yet from the catalyst information. Not a patient. So it'll be very interesting to see where that goes over time.

All right. Looking forward to the full data. And on generic, are you seeing any impact to Coraline since Taylor's generic launch six weeks ago? And have you or do you plan to institute any new sales strategy in response to generic launch? Thank you.

June, I'm going to give you back to Sean for that question. Yeah, no, June, thanks for the question. There has been no impact to our business since Dev announced its launch. We have seen no evidence of generic Mifepristone in the marketplace, and we're monitoring daily. And to your second question, you know, I'm not going to go into any specifics, but, again, we've been prepared. We have a plan in place, and we're to follow.

Thank you. Thank you. There are no further questions in the queue.

All right. Well, thank you, everybody, and I look forward to three months from you speaking with you again, and hope you have a good rest of the winter and early spring.

Thank you all for joining today's conference call. You may disconnect.